Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1L | First-line treatment |
| 2L | Second-line treatment |
| 3L | Third-line treatment |
| ADA | Antidrug antibody |
| AHFS | American Hospital Formulary Service |
| ALK | Anaplastic lymphoma kinase |
| ASCO | American Society of Clinical Oncology |
| ASP | Average sales price |
| AUC | Area under the concentration-time curve |
| BC | Breast cancer |
| BICR | Blinded independent central review |
| BLA | Biologics license application |
| CI | Confidence interval |
| CNS | Central nervous system |
| CP | Current-practice scenario |
| CSCO | Chinese Society of Clinical Oncology |
| CT | Computed tomography |
| CTCAE | Common Terminology Criteria for Adverse Events |
| DCR | Disease control rate |
| DOR | Duration of response |
| ECOG | Eastern Cooperative Oncology Group |
| EGFR | Epidermal growth factor receptor |
| EGFRm | EGFR-mutated |
| EMA | European Medicines Agency |
| ESMO | European Society for Medical Oncology |
| FDA | U.S. Food and Drug Administration |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| ICER | Incremental cost-effectiveness ratio |
| IgG1 | Immunoglobulin G1 |
| IRRC | Independent radiology review committee |
| ITT | Intention to treat |
| IV | Intravenous |
| LY | Life-year |
| MET | MET proto-oncogene, receptor tyrosine kinase |
| MPE | Malignant pleural effusion |
| MTD | Maximum tolerated dose |
| NE | Not estimable |
| NGS | Next-generation sequencing |
| NMPA | National Medical Products Administration |
| NSCLC | Non-small-cell lung cancer |
| ORR | Objective response rate |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PDUFA | Prescription Drug User Fee Act |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| PPPM | Per patient per month |
| PRO | Patient-reported outcome |
| Q2W | Every 2 weeks |
| Q3W | Every 3 weeks |
| QALY | Quality-adjusted life-year |
| RCT | Randomized controlled trial |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| SGT | Single-gene testing |
| TEAE | Treatment-emergent adverse event |
| TKI | Tyrosine kinase inhibitor |
| TRAE | Treatment-related adverse event |
| VEGF | Vascular endothelial growth factor |
| WAC | Wholesale acquisition cost |
| WTP | Willingness to pay |